MAIA Biotechnology, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2022


	Shares			Weighted Average Grant Date Fair Value
Unvested balance at January 1, 2022		58,333		$	1.80
Vested		(58,333	)		1.80
Unvested balance at December 31, 2022		—		$	—

Schedule Of Warrant Exercised


	Warrants Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
Balance at January 1, 2022		1,311,117		$	4.03		7.30
Issued		115,000			6.25
Exercised		(608,612	)		1.80
Expired		(20,520	)		5.00
Balance at December 31, 2022		796,985		$	6.04		5.16

Assumptions Used in Calculating Value of Warrants Granted

The value of the warrants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for warrants granted during the years ended December 31, 2022 and 2021:

	2022	2021
Risk-free interest rate	2.8% - 4.1%	0.6% - 1.3%
Expected term (in years)	4.6 - 5	5 - 7
Expected volatility	78% - 92%	81% - 106%
Expected dividend yield	—%	—%

The value of option grants are calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the years ended December 31, 2022 and 2021.


	2022		2021
Risk-free interest rate	2.14% - 4.45%		0.36% - 1.27%
Expected term (in years)	5 - 6.25		5 - 6.50
Expected volatility	71.9% - 87.9%		71.4% - 81.5%
Expected dividend yield		—		—

Summary of Activity and Information Regarding Outstanding and Exercisable Options

The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options classified as equity awards as of December 31, 2022:


	Options Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Balance at January 1, 2022		5,797,185		$	2.22		8.59		—
Granted		811,831			4.77
Exercised		(46,500	)		1.81
Cancelled/forfeited		(16,888	)		1.82
Balance at December 31, 2022		6,545,628		$	2.55		7.85	$	9,773,706
Options exercisable at December 31, 2022		5,449,715		$	2.24		7.59	$	8,804,841

Summary of Stock Based Compensation Expense

Stock based compensation related to the Company’s stock plans are as follows:


	Years Ended December 31,

	2022		2021
General and administrative	$	1,422,799	$	1,779,185
Research and development		896,628		943,708
Total stock-based compensation	$	2,319,427	$	2,722,893